During the first 3-1/2 years of the present five-year grant period (i.e., October, 1987, to the present), Project I.2 concentrated on methods for analyzing volatile and semivolatile toxicants in air samples, and application of the methods to the characterization of various effluents at or near sources and downward from them. During the renewal period, we will continue these efforts and will expand on the more promising methods and their applications. These methods include superficial fluid extraction (SFE) of air sampling media, and its interfacing with mutagen bioassay, immunoassay, and GC or GC-MS analysis. New directions for SFE will involve programmed extraction for fractionating mixtures and interfacing with other bioassays, including those using fish. Another promising line of study involved measuring flux using both aerodynamic and chamber methods, which will be continued with the addition of laboratory micro-chambers as field simulators, and in situ field flux analyses with a new FT-IR system. The remaining line to be continued-quantifying downwind distributions and their effects using fog sampling and indicator metabolites in humans-will be expanded to include marker chemicals indicative of toxic waste sites, combustion sources, vehicular exhaust, and other sources, and by interfacing with an ongoing project using wild sentinel animals as indicators of exposure and air quality. An expanded theme through all components of the project will be to determine the biological significance of airborne residues, by focusing on methods which can accommodate biological assay and by strengthened collaborations with other Superfund investigators having assessment capabilities. Specific objectives include the following: I. Develop methods for sampling and analyzing vapors of toxicants in the air overlying and downwind from waste sites. II. Develop methods for determining volatilization flux of chemicals from soil and water. III. Determine toxic residue content of ambient air, rainwater, and fogwater samples collected near waste disposal sites.

Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of California Davis
Department
Type
DUNS #
094878337
City
Davis
State
CA
Country
United States
Zip Code
95618
Taha, Ameer Y; Hennebelle, Marie; Yang, Jun et al. (2018) Regulation of rat plasma and cerebral cortex oxylipin concentrations with increasing levels of dietary linoleic acid. Prostaglandins Leukot Essent Fatty Acids 138:71-80
Hill 3rd, Thomas; Rice, Robert H (2018) DUOX expression in human keratinocytes and bronchial epithelial cells: Influence of vanadate. Toxicol In Vitro 46:257-264
Kodani, Sean D; Wan, Debin; Wagner, Karen M et al. (2018) Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors. ACS Omega 3:14076-14086
Ren, Qian; Ma, Min; Yang, Jun et al. (2018) Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease. Proc Natl Acad Sci U S A 115:E5815-E5823
Pecic, Stevan; Zeki, Amir A; Xu, Xiaoming et al. (2018) Novel piperidine-derived amide sEH inhibitors as mediators of lipid metabolism with improved stability. Prostaglandins Other Lipid Mediat 136:90-95
Yamanashi, Haruto; Boeglin, William E; Morisseau, Christophe et al. (2018) Catalytic activities of mammalian epoxide hydrolases with cis and trans fatty acid epoxides relevant to skin barrier function. J Lipid Res 59:684-695
Wang, Fuli; Zhang, Hongyong; Ma, Ai-Hong et al. (2018) COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin. Mol Cancer Ther 17:474-483
Napimoga, M H; Rocha, E P; Trindade-da-Silva, C A et al. (2018) Soluble epoxide hydrolase inhibitor promotes immunomodulation to inhibit bone resorption. J Periodontal Res 53:743-749
Blöcher, René; Wagner, Karen M; Gopireddy, Raghavender R et al. (2018) Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain. J Med Chem 61:3541-3550
Hao, Lei; Kearns, Jamie; Scott, Sheyenne et al. (2018) Indomethacin Enhances Brown Fat Activity. J Pharmacol Exp Ther 365:467-475

Showing the most recent 10 out of 1149 publications